Key Takeaways:
- FDA approved Foundayo (orforglipron) on May 5, 2026, as the second GLP-1 pill for weight loss in the US
- Unlike Wegovy pill, Foundayo can be taken anytime with or without food, offering greater convenience
- Starting at $149/month self-pay, with $25/month for insured patients and $50/month for Medicare starting July 2026
- Record-fast 50-day approval through FDA's National Priority Voucher program - fastest new drug approval since 2002
The FDA has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems, marking a significant milestone in GLP-1 obesity treatment. This approval, announced May 5, 2026, makes Foundayo the second oral GLP-1 medication available for weight loss in the United States, following Novo Nordisk's Wegovy pill approval in December 2025.
Historic Fast-Track Approval Sets New Standard
The FDA issued approval within 50 days after filing — 294 days before the application's standard review date of January 20, 2027 — representing the fastest approval of a new molecular entity since 2002. This record-breaking timeline came through the FDA's Commissioner's National Priority Voucher (CNPV) pilot program, designed to accelerate access to important new treatments.
"This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners," said FDA Commissioner Martin Makary, M.D., M.P.H.
Key Advantage: No Food or Timing Restrictions
While both Foundayo and the Wegovy pill offer needle-free GLP-1 treatment, Foundayo provides significantly more flexibility. Oral semaglutide products like Wegovy pill must be taken on an empty stomach with a small sip of water, followed by a waiting period before eating or drinking. Foundayo has none of these restrictions and can be taken once daily at any time, with or without food.
This convenience factor addresses a major barrier for people considering GLP-1 treatment. Unlike injectable semaglutide, which requires weekly shots, Foundayo offers a more flexible daily routine. "For many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Dr. Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston.
Clinical Results Show Strong Weight Loss
In clinical trials, Foundayo delivered an average of 12% weight loss at the highest dose over 72 weeks, compared with 0.9% for people taking a placebo. While this is somewhat lower than injectable GLP-1 drugs that achieve over 20% weight loss, it represents meaningful results for an oral medication.
Foundayo is taken once daily starting at 0.8 mg, increasing to 2.5 mg after 30 days, then to 5.5 mg after another 30 days. The dosage may be increased further to 9 mg, 14.5 mg, or 17.2 mg based on treatment response and tolerability.
The titration schedule allows your body to gradually adjust to the medication, potentially reducing side effects that can occur when starting GLP-1 treatments. Most people in the trials reached the target maintenance dose within 90 days.
Affordable Pricing Breaks Access Barriers
Eli Lilly has positioned Foundayo as an accessible option with competitive pricing across insurance types. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card, while individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose.
For Medicare beneficiaries, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026. This represents a significant step forward in Medicare coverage for weight loss medications.
The pricing structure makes Foundayo competitive with other GLP-1 options currently available. You can compare these costs and explore your coverage options in our detailed cost guide.
Addressing the Treatment Gap
"Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment," said David A. Ricks, chair and CEO of Eli Lilly. The convenience and accessible pricing of Foundayo could help bridge this treatment gap.
Lilly estimates that the pills might appeal to people who "have less severe obesity" who haven't wanted to try a weekly injection, potentially expanding the pool of people willing to start GLP-1 treatment.
This broader appeal could be particularly important for people who are overweight with related health conditions like type 2 diabetes or high blood pressure, but who haven't reached obesity levels that typically qualify for injectable treatments.
Safety Profile Similar to Other GLP-1 Drugs
The most common side effects for Foundayo are similar to those for other GLP-1 drugs: nausea, constipation and other gastrointestinal effects. Some people also experience hair loss. The labeling includes a boxed warning for thyroid C-cell tumors, and Foundayo should not be used in patients with a personal or family history of medullary thyroid cancer.
Lilly noted the drug's safety hasn't been established during pregnancy, and that people taking birth control pills should talk with their doctors about potentially starting another prevention method as birth control pills may not work as well while patients are taking Foundayo.
If you're currently taking hormonal birth control, discuss alternative contraception methods with your healthcare provider before starting Foundayo. The interaction appears related to how GLP-1 medications slow gastric emptying, which can affect the absorption of oral contraceptives.
What This Means for You
The approval of Foundayo significantly expands your options for GLP-1 weight loss treatment. If you've been hesitant about weekly injections or found the strict dosing requirements of other oral options challenging, Foundayo's flexibility might be the right fit. With self-pay pricing starting at $149 monthly and potential insurance coverage bringing costs down to $25-$50 monthly, it's positioned as one of the more accessible GLP-1 options.
Foundayo will be available via LillyDirect, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers. You can find telehealth providers that offer Foundayo or search for local clinics that may prescribe it.
Consider discussing Foundayo with your healthcare provider if you meet the criteria for GLP-1 treatment but have been deterred by injection requirements or complex dosing schedules. The medication may be particularly suitable if you have a busy lifestyle that makes the strict timing requirements of other oral GLP-1 medications difficult to follow.
Sources
- FDA Approves First New Molecular Entity Under National Priority Voucher Program - FDA official announcement
- Eli Lilly announces FDA approval of Foundayo - Company press release
- CNN coverage of Foundayo approval - Clinical trial data and pricing details
- Drugs.com FDA approval history - Clinical study results and safety information